Appili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral Suspension
(RTTNews) - Biopharmaceutical company Appili Therapeutics, Inc. (APLI.TO, APLIF.PK) announced Monday that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC received approval from the U.S. Food and Drug Administration (FDA) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).
ATI-1501, Appili's liquid oral reformulation of the antibiotic metronidazole, has been licensed to Saptalis for commercialization in the U.S., and other selected territories. The FDA also approved LIKMEZ as the brand name for ATI-1501.
Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the U.S. every year to help treat parasitic and anaerobic bacterial infections.
The current tablet form of metronidazole is the only other approved oral form on the U.S. market.
Appili expects to receive milestone payments and royalties from Saptalis based on this FDA approval and Saptalis' commercialization plans.
European Shares Seen Mostly Lower Before US Inflation Data
Sensex, Nifty Struggle For Direction In Early Trade
Australian Market Swings To Modest Gains In Mid-market
Asian Markets Mixed Amid Caution Trades
Sensex, Nifty Seen Tad Higher At Open As IIP Growth Recovers
Thai Stock Market Tipped To Open In The Green
Japanese Market Notably Lower
